Details

Autor(en) / Beteiligte

• Conaghan, Philip G.
• Hensor, Elizabeth M. A.
• Keenan, Anne-Maree
• Morgan, Ann W.
• Emery, Paul

Titel

Persistently moderate DAS-28 is not benign: loss of function occurs in early RA despite step-up DMARD therapy

Ist Teil von

• Rheumatology (Oxford, England), 2010-10, Vol.49 (10), p.1894-1899

Ort / Verlag

Oxford: Oxford University Press

Erscheinungsjahr

2010

Link zum Volltext

Quelle

Oxford Journals 2020 Medicine

Beschreibungen/Notizen

• Objectives. Current UK management of RA initially employs conventional DMARDs, with biological therapy reserved for DMARD-resistant RA patients with persistently high 28-joint disease activity score (DAS-28). The aim of this study was to examine the effect on patient-reported function of persistently moderate DAS-28 despite modern step-up DMARD therapy in an early arthritis cohort. Methods. Data were obtained from the Yorkshire Early Arthritis Register, a cohort of early (<12 months) RA patients treated with dose-escalated DMARDs. Change in HAQ exceeding the minimum clinically important difference (MCID) was determined for three values of MCID (0.22, 0.31 and 0.49). Changes in HAQ over Months 6–12 were compared between patients whose DAS-28(ESR) was persistently high (>5.1 at 6- and/or 9-month visits and at the 12-month visit), persistently moderate (>3.2 and ≤5.1) or persistently low (≤3.2). Results. We selected 194 patients for this analysis. Deteriorating HAQ scores were observed in 10.9% of patients with persistently low DAS-28 compared with 21.4% (persistently moderate DAS-28) and 46.7% (persistently high DAS-28), respectively, for MCID = 0.22; 7.3, 14.3 and 20.0% for MCID = 0.31; 5.5, 10.7 and 11.1% for MCID = 0.49. Conclusions. A high DAS-28 was generally associated with a greater degree of functional decline, but persistent moderate elevation of DAS-28 was associated with important functional deterioration in 10–21% of early RA patients (depending on choice of MCID) following a modern DMARD protocol. A proportion of patients with persistently moderate DAS-28 may therefore benefit from more aggressive therapy than that allowed by current UK recommendations.